Evidence map›Paper›PMID 29877607›Full record

ArticleClinical and translational science2018

Effect of Dose and 5α-Reductase Inhibition on the Circulating Testosterone Metabolite Profile of Men Administered Oral Testosterone.

Abdul Basit, John K Amory, Bhagwat Prasad

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Relevance of Human Aldoketoreductases and MicrobialDrug metabolism and disposition: the biological fate of chemicals · 2023
    Article
  2. Article
  3. Impact of Microbiome on Hepatic Metabolizing Enzymes and Transporters in Mice during Pregnancy.Drug metabolism and disposition: the biological fate of chemicals · 2020
    Article
  4. Article
  5. The gut microbiota is a major regulator of androgen metabolism in intestinal contents.American journal of physiology. Endocrinology and metabolism · 2019
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Abdul BasitDepartment of Pharmaceutics, University of Washington, Seattle, Washington, USA.
John K AmoryDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Bhagwat PrasadDepartment of Pharmaceutics, University of Washington, Seattle, Washington, USA.
University of Washington · US

Funding

PBPK prediction of ontogeny mediated alteration in hepatic drug eliminationR01HD081299 · NICHD · WASHINGTON STATE UNIVERSITY · PI PRASAD, BHAGWAT · 2015 to 2025
$4.6M
Retinoic Acid in Male InfertilityK24HD082231 · NICHD · UNIVERSITY OF WASHINGTON · PI AMORY, JOHN K. · 2015 to 2019
$638k
NICHD NIH HHS K24 HD082231NICHD NIH HHS R01 HD081299
6 · The paper itself

Abstract

Development of an oral testosterone therapy has proven extremely challenging because of extensive and variable first-pass metabolism. We investigated the in vivo metabolism of testosterone with increasing oral doses of testosterone, both alone and with the co-administration of dutasteride (5α-reductase inhibitor) by liquid-chromatography tandem mass spectrometry (LC-MS/MS). In eugonadal men prior to dosing, the circulating concentration of testosterone, androstenedione, etiocholanolone-glucuronide, and androsterone-glucuronide was 8.6, 20.9, 9.1, and 55.3%, respectively, of the total testosterone-related species, whereas testosterone-glucuronide was ∼1%. When testosterone was dosed orally to men with experimental hypogonadism, a proportion of testosterone-glucuronide increased to 13%. Dutasteride treatment significantly decreased levels of androsterone and its metabolites. This work reveals extensive metabolism of orally dosed testosterone to androsterone glucuronide via androstenedione, with testosterone-glucuronide appearing to be the second most important metabolite. This information is of importance in the development of an effective oral testosterone therapy and may have implications for testosterone doping research.

Indexed as

Metabolome5-alpha Reductase InhibitorsAdministration, OralArea Under CurveDose-Response Relationship, DrugDutasterideGlucuronidesGlucuronosyltransferaseHepatocytesHumansMaleTestosterone5-alpha Reductase InhibitorsDutasterideGlucuronidesGlucuronosyltransferaseTestosterone

Identifiers

PMID29877607
PMCPMC6132360
OpenAlexW2805580013

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.